Chartwell Partners Recruits Ian Hunt to Akebia Therapeutics as SVP, Regulatory Affairs

We are delighted to announce the recruitment of Ian Hunt as SVP, Regulatory Affairs for Akebia Therapeutics, a public, Cambridge, MA-based biopharmaceutical company committed to bettering the lives of people impacted by kidney disease. Most recently, Ian served as Vice President and Head of Regulatory Affairs for GSK’s Infectious Disease, Neuroscience and CV/Renal franchises, a position he held since August 2016. Previously, Ian spent 28 years with AstraZeneca and its predecessor companies, driving regulatory strategy and regional submissions for multiple products, including Crestor®, Brilinta®, Farxiga®, Bydureon®, and Myalept®. The breadth of Ian’s global regulatory leadership experience and specific expertise in the renal space will be great assets to Akebia as the company focuses on gaining FDA and EMA approval for vadadustat, Akebia’s oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia due to chronic kidney disease, and future product candidates.